Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study

Yuan-Hao Yang,Jen-Kou Lin,Wei-Shone Chen,Tzu-Chen Lin,Shung-Haur Yang,Jeng-Kai Jiang,Yuan-Tzu Lan,Chun-Chi Lin,Chueh-Chuan Yen,Cheng-Hwai Tzeng,Hao-Wei Teng

Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study

2014

Yuan-Hao Yang
Jen-Kou Lin
Wei-Shone Chen
Tzu-Chen Lin
Shung-Haur Yang
Jeng-Kai Jiang
Yuan-Tzu Lan
Chun-Chi Lin
Chueh-Chuan Yen
Cheng-Hwai Tzeng
Hao-Wei Teng

Purpose We aimed to compare the treatment efficacy of cetuximab versus bevacizumab in combination with either irinotecan-based or oxaliplatin-based regimens (targeted triplet) as the first-line treatment for patients with metastatic colorectal cancer.

Keywords:

Cetuximab
Bevacizumab
KRAS
Colorectal cancer
Progression-free survival
Oxaliplatin
Irinotecan
Oncology
Metastasectomy
Internal medicine
Biology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations